Novo Nordisk A/S KOPENHAGA: NOVO B, NYSE: NVO p. farmaceutyczny, producent m.in. insuliny, leków na hemofilię

czyli wszystkie giełdy bardziej rozwinięte niż GPW
slayer74
Porucznik
Posty: 35410
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: Novo Nordisk A/S KOPENHAGA: NOVO B, NYSE: NVO p. farmaceutyczny producent m.in. insuliny, leków na hemofilię

Postautor: slayer74 » 20 gru 2021 10:11

Novo Nordisk shares slump on obesity drug supply challenges

COPENHAGEN (Reuters) – Novo Nordisk shares fell 16% :shock: on Monday after the Danish drugmaker late on Friday announced that it will not be able to meet demand for its new weight-loss drug after supply issues in the United States.

COPENHAGEN (Reuters) -Novo Nordisk shares fell as much as 16% on Monday after the Danish drugmaker was hit by U.S. supply issues for its new obesity drug as it seeks to establish a market foothold before the launch of a rival drug by Eli Lilly.

https://www.fxempire.com/news/article/n ... rug-845579
...
Deutsche Bank Aktiengesellschaft Lowers Novo Nordisk A/S (NYSE:NVO) to Hold

Deutsche Bank Aktiengesellschaft lowered shares of Novo Nordisk A/S (NYSE:NVO) from a buy rating to a hold rating in a report issued on Friday, Analyst Price Targets reports.

NVO has been the subject of several other research reports. SEB Equities upgraded Novo Nordisk A/S from a hold rating to a buy rating in a research report on Monday, October 18th. Citigroup reiterated a buy rating on shares of Novo Nordisk A/S in a research report on Monday, August 23rd. UBS Group reiterated a neutral rating on shares of Novo Nordisk A/S in a research report on Thursday, November 11th. Bryan, Garnier & Co downgraded Novo Nordisk A/S from a buy rating to a sell rating and set a 592.00 price objective on the stock. in a report on Wednesday, November 3rd. Finally, Berenberg Bank reiterated a hold rating on shares of Novo Nordisk A/S in a report on Friday, September 3rd. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, Novo Nordisk A/S currently has a consensus rating of Hold and a consensus price target of $341.50.

NYSE NVO opened at $107.45 on Friday. Novo Nordisk A/S has a 52 week low of $66.59 and a 52 week high of $117.35. The company has a quick ratio of 0.82, a current ratio of 1.03 and a debt-to-equity ratio of 0.19. The business’s fifty day simple moving average is $109.49 and its 200-day simple moving average is $99.21. The firm has a market cap of $253.02 billion, a PE ratio of 33.47, a P/E/G ratio of 2.88 and a beta of 0.44.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Tuesday, November 2nd. The company reported $5.27 earnings per share for the quarter, beating the consensus estimate of $0.78 by $4.49. Novo Nordisk A/S had a return on equity of 73.70% and a net margin of 34.33%. Research analysts expect that Novo Nordisk A/S will post 3.27 EPS for the current year.

Several hedge funds have recently bought and sold shares of the company. Two Sigma Advisers LP raised its stake in Novo Nordisk A/S by 345.8% during the 3rd quarter. Two Sigma Advisers LP now owns 715,900 shares of the company’s stock worth $68,734,000 after buying an additional 555,300 shares during the period. Amundi acquired a new stake in Novo Nordisk A/S during the 2nd quarter worth $45,181,000. Folketrygdfondet raised its stake in Novo Nordisk A/S by 11.0% during the 2nd quarter. Folketrygdfondet now owns 4,715,517 shares of the company’s stock worth $395,019,000 after buying an additional 466,107 shares during the period. Bank of Montreal Can raised its stake in Novo Nordisk A/S by 289.7% during the 2nd quarter. Bank of Montreal Can now owns 619,623 shares of the company’s stock worth $51,993,000 after buying an additional 460,625 shares during the period. Finally, Arrowstreet Capital Limited Partnership acquired a new stake in Novo Nordisk A/S during the 3rd quarter worth $37,246,000. 5.58% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the following segments: Diabetes & Obesity Care, and Biopharmaceuticals. The Diabetes & Obesity Care segment covers products for insulin; GLP-1 and related delivery systems; oral antidiabetic products; and obesity.

https://etfdailynews.com/news/deutsche- ... o-to-hold/
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!


slayer74
Porucznik
Posty: 35410
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: Novo Nordisk A/S KOPENHAGA: NOVO B, NYSE: NVO p. farmaceutyczny producent m.in. insuliny, leków na hemofilię

Postautor: slayer74 » 22 gru 2021 14:34

Novo Nordisk A/S (NYSE:NVO) Rating Lowered to Hold at Danske

Novo Nordisk A/S (NYSE:NVO) was downgraded by research analysts at Danske from a “buy” rating to a “hold” rating in a report issued on Monday, The Fly reports.

Several other brokerages also recently commented on NVO. Citigroup restated a “buy” rating on shares of Novo Nordisk A/S in a research report on Monday, August 23rd. Morgan Stanley reaffirmed an “underweight” rating on shares of Novo Nordisk A/S in a research note on Tuesday, November 2nd. Bryan, Garnier & Co cut Novo Nordisk A/S from a “buy” rating to a “sell” rating and set a 592.00 target price on the stock. in a research note on Wednesday, November 3rd. SEB Equities raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Monday, October 18th. Finally, UBS Group reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a research report on Thursday, November 11th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $341.50.

Shares of NVO opened at $106.21 on Monday. The stock’s 50-day simple moving average is $109.76 and its 200 day simple moving average is $99.56. Novo Nordisk A/S has a 52-week low of $66.59 and a 52-week high of $117.35. The stock has a market capitalization of $250.10 billion, a price-to-earnings ratio of 33.09, a price-to-earnings-growth ratio of 2.72 and a beta of 0.44. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.82 and a current ratio of 1.03.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Tuesday, November 2nd. The company reported $5.27 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.78 by $4.49. Novo Nordisk A/S had a return on equity of 73.70% and a net margin of 34.33%. On average, research analysts forecast that Novo Nordisk A/S will post 3.27 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Moors & Cabot Inc. grew its position in Novo Nordisk A/S by 233.9% during the 3rd quarter. Moors & Cabot Inc. now owns 8,728 shares of the company’s stock worth $836,000 after purchasing an additional 6,114 shares during the period. JB Capital LLC acquired a new stake in shares of Novo Nordisk A/S during the 3rd quarter valued at about $466,000. Patriot Financial Group Insurance Agency LLC grew its position in shares of Novo Nordisk A/S by 947.5% during the 3rd quarter. Patriot Financial Group Insurance Agency LLC now owns 5,447 shares of the company’s stock valued at $523,000 after acquiring an additional 4,927 shares during the period. Fortis Advisors LLC acquired a new stake in shares of Novo Nordisk A/S during the 3rd quarter valued at about $29,000. Finally, EP Wealth Advisors LLC grew its position in shares of Novo Nordisk A/S by 19.3% during the 3rd quarter. EP Wealth Advisors LLC now owns 4,217 shares of the company’s stock valued at $405,000 after acquiring an additional 683 shares during the period. 5.58% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the following segments: Diabetes & Obesity Care, and Biopharmaceuticals. The Diabetes & Obesity Care segment covers products for insulin; GLP-1 and related delivery systems; oral antidiabetic products; and obesity.
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!

slayer74
Porucznik
Posty: 35410
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: Novo Nordisk A/S KOPENHAGA: NOVO B, NYSE: NVO p. farmaceutyczny producent m.in. insuliny, leków na hemofilię

Postautor: slayer74 » 14 sty 2022 18:20

Investing.com — Novo Nordisk A/S (NYSE:NVO) said Friday that it has settled a securities lawsuit in Denmark.

Shares of Novo fell 3% in midday trading.

The company said the settlement contained no admission of liability, wrongdoing or responsibility and Novo Nordisk is not making any payment.

The 2019 lawsuit alleged the company made misleading statements and did not make appropriate disclosures regarding its insulin business in the United States.

The lawsuit was filed by several shareholders claiming compensation worth 11.785 billion Danish crowns or approximately $1.75 billion.

At the time, Novo said it "disagrees with the allegations and is prepared to defend the company in this matter."
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!

slayer74
Porucznik
Posty: 35410
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: Novo Nordisk A/S KOPENHAGA: NOVO B, NYSE: NVO p. farmaceutyczny, producent m.in. insuliny, leków na hemofilię

Postautor: slayer74 » 17 sty 2022 20:34

Obrazek

Dawno tyle sesji spadkowych nie było :twisted:
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!


Wróć do „Zagranica”

REKLAMA

Kto jest online

Użytkownicy przeglądający to forum: Obecnie na forum nie ma żadnego zarejestrowanego użytkownika i 4 gości